Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/101587
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorMainland Development Office-
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorZhang, Yen_US
dc.creatorLi, XLen_US
dc.creatorSha, NNen_US
dc.creatorShu, Ben_US
dc.creatorZhao, YJen_US
dc.creatorWang, XLen_US
dc.creatorXiao, HHen_US
dc.creatorShi, Qen_US
dc.creatorWong, MSen_US
dc.creatorWang, YJen_US
dc.date.accessioned2023-09-18T07:31:20Z-
dc.date.available2023-09-18T07:31:20Z-
dc.identifier.issn8756-3282en_US
dc.identifier.urihttp://hdl.handle.net/10397/101587-
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2017 Elsevier Inc. All rights reserved.en_US
dc.rights© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.rightsThe following publication Zhang, Y., Li, X. L., Sha, N. N., Shu, B., Zhao, Y. J., Wang, X. L., ... & Wang, Y. J. (2017). Differential response of bone and kidney to ACEI in db/db mice: A potential effect of captopril on accelerating bone loss. Bone, 97, 222-232 is available at https://doi.org/10.1016/j.bone.2017.01.029.en_US
dc.subjectBoneen_US
dc.subjectCaptoprilen_US
dc.subjectDiabetesen_US
dc.subjectKidneyen_US
dc.subjectOsteoporosisen_US
dc.subjectRenin-angiotensin systemen_US
dc.titleDifferential response of bone and kidney to ACEI in db/db mice : a potential effect of captopril on accelerating bone lossen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage222en_US
dc.identifier.epage232en_US
dc.identifier.volume97en_US
dc.identifier.doi10.1016/j.bone.2017.01.029en_US
dcterms.abstractThe components of renin-angiotensin system (RAS) are expressed in the kidney and bone. Kidney disease and bone injury are common complications associated with diabetes. This study aimed to investigate the effects of an angiotensin-converting enzyme inhibitor, captopril, on the kidney and bone of db/db mice. The db/db mice were orally administered by gavage with captopril for 8 weeks with db/+ mice as the non-diabetic control. Serum and urine biochemistries were determined by standard colorimetric methods or ELISA. Histological measurements were performed on the kidney by periodic acid-schiff staining and on the tibial proximal metaphysis by safranin O and masson-trichrome staining. Trabecular bone mass and bone quality were analyzed by microcomputed tomography. Quantitative polymerase chain reaction and immunoblotting were applied for molecular analysis on mRNA and protein expression. Captopril significantly improved albuminuria and glomerulosclerosis in db/db mice, and these effects might be attributed to the down-regulation of angiotensin II expression and the expression of its down-stream profibrotic factors in the kidney, like connective tissue growth factor and vascular endothelial growth factor. Urinary excretion of calcium and phosphorus markedly increased in db/db mice in response to captopril. Treatment with captopril induced a decrease in bone mineral density and deterioration of trabecular bone at proximal metaphysis of tibia in db/db mice, as shown in the histological and reconstructed 3-dimensional images. Even though captopril effectively reversed the diabetes-induced changes in calcium-binding protein 28-k and vitamin D receptor expression in the kidney as well as the expression of RAS components and bradykinin receptor-2 in bone tissue, treatment with captopril increased the osteoclast-covered bone surface, reduced the osteoblast-covered bone surface, down-regulated the expression of type 1 collagen and transcription factor runt-related transcription factor 2 (markers for osteoblastic functions), and up-regulated the expression of carbonic anhydrase II (marker for bone resorption). Captopril exerted therapeutic effects on renal injuries associated with type 2 diabetes but worsened the deteriorations of trabecular bone in db/db mice; the latter of which was at least in part due to the stimulation of osteoclastogenesis and the suppression of osteogenesis by captopril.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationBone, Apr. 2017, v. 97, p. 222-232en_US
dcterms.isPartOfBoneen_US
dcterms.issued2017-04-
dc.identifier.scopus2-s2.0-85011263954-
dc.identifier.pmid28130181-
dc.description.validate202308 bckw-
dc.description.oaAccepted Manuscripten_US
dc.identifier.FolderNumberABCT-0656-
dc.description.fundingSourceOthersen_US
dc.description.fundingTextMinistry of Science and Technology; Ministry of Education (Innovative Research Team in University); Longhua Medical Innovation Team Program; NSFC; Natural Science Foundation of Shanghaien_US
dc.description.pubStatusPublisheden_US
dc.identifier.OPUS6719197-
dc.description.oaCategoryGreen (AAM)en_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Wong_Differential_Response_Bone.pdfPre-Published version1.46 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Final Accepted Manuscript
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

85
Citations as of Apr 14, 2025

Downloads

100
Citations as of Apr 14, 2025

SCOPUSTM   
Citations

20
Citations as of Dec 19, 2025

WEB OF SCIENCETM
Citations

18
Citations as of Dec 18, 2025

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.